TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy
Although immune checkpoint blockade therapies targeting PD-1/PD-L1 and CTLA-4 have achieved remarkable clinical success, limitations such as low response rates and acquired resi...